
Multiple Sclerosis MS drug almost halves risk of severe Covid symptoms
A drug used for multiple sclerosis nearly halves the chance of developing severe coronavirus symptoms in hospitalised patients and may prevent deaths, a new trial has shown.
Covid patients at nine hospitals including Southampton General were given an inhaled version of the treatment interferon beta-1a and were twice as likely to recover within 14 days as those in the placebo arm of the trial, even though they were sicker to begin with.
Image by fernando zhiminaicela from Pixabay
** This post was originally published on November 13, 2020 **